Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053201 | 0.81 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DSLC22A12 | |
| SCHEMBL11752418 | 0.78 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DSLC22A12 | |
| SCHEMBL7052318 | 0.77 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DSLC22A12 | |
| SCHEMBL3835928 | 0.73 | KCNA3 (0.44) | CDC25B | |
| SCHEMBL1287513 | 0.72 | SLC22A12 (0.67) | PDE4APDE4BPDE4CPDE4DSLC22A12 | |
| SCHEMBL2261166 | 0.71 | SLC22A12 (0.64) | PDE4APDE4BPDE4CPDE4DSLC22A12 | |
| SCHEMBL6605574 | 0.69 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL3924757 | 0.68 | KDM4E (0.49) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL14124722 | 0.68 | CDC25B (0.64) | KDM4EHPGDSCYP3A4CDC25B | |
| SCHEMBL7051464 | 0.68 | PDE4D (0.76) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | PDE4A 412/4885PDE4B 484/4885PDE4C 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.